文献速递血栓与止血

利伐沙班治疗非肝硬化内脏静脉血栓:一项干预性前瞻性队列研究

Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study.
PubMed 文献 · Blood Adv · 2022-01-01

这项国际单臂临床试验评估利伐沙班治疗急性非肝硬化症状性内脏静脉血栓的安全性和有效性,100例可分析患者接受利伐沙班15mg每日两次3周后20mg每日一次至3个月。3个月时大出血发生率2.1%(95%CI 0.6-7.2),复发性SVT 2.1%,完全再通率47.3%。利伐沙班似乎是标准抗凝的潜在替代选择。

要点

  • 3个月时大出血2例(2.1%;95%CI 0.6-7.2),均为消化道出血。
  • 3个月时复发性SVT 2例(2.1%),死亡1例(1.0%)为非SVT相关原因。
  • 3个月时完全再通率为47.3%,6个月时额外发生1例大出血和1例复发性SVT。

核心结论

  • 利伐沙班似乎是非肝硬化患者内脏静脉血栓治疗中标准抗凝的潜在替代选择。

研究设计与样本

  • 国际、单臂临床试验;入组103例,100例符合分析;成人首次发作非肝硬化、症状性、客观诊断的内脏静脉血栓。
  • 患者接受利伐沙班15 mg每日两次共3周,随后20 mg每日一次,预期疗程3个月;随访共6个月。
  • 排除Budd-Chiari综合征患者及入组前接受全剂量抗凝超过7天的患者。

主要发现

  • 平均年龄54.4岁,64%为男性;SVT危险因素包括腹腔炎症/感染(28%)、实体癌(9%)、骨髓增殖性肿瘤(9%)、激素治疗(9%),43%为无诱因。
  • 50例受检患者中26%检出JAK2 V617F突变。
  • 3个月时2例(2.1%;95%CI 0.6-7.2)发生大出血(均为消化道出血);1例(1.0%)死于非SVT相关原因;2例(2.1%)复发SVT;47.3%记录到完全再通。
  • 6个月时额外发生1例大出血和1例复发性SVT。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heparins and vitamin K antagonists are the mainstay of treatment of splanchnic vein thrombosis (SVT). Rivaroxaban is a potential alternative, but data to support its use are limited. We aimed to evaluate the safety and efficacy of rivaroxaban for the treatment of acute SVT. In an international, single-arm clinical trial, adult patients with a first episode of noncirrhotic, symptomatic, objectively diagnosed SVT received rivaroxaban 15 mg twice daily for 3 weeks, followed by 20 mg daily for an intended duration of 3 months. Patients with Budd-Chiari syndrome and those receiving full-dose anticoagulation for >7 days prior to enrollment were excluded. Primary outcome was major bleeding; secondary outcomes included death, recurrent SVT, and complete vein recanalization within 3 months. Patients were followed for a total of 6 months. A total of 103 patients were enrolled; 100 were eligible for the analysis. Mean age was 54.4 years; 64% were men. SVT risk factors included abdominal inflammation/infection (28%), solid cancer (9%), myeloproliferative neoplasms (9%), and hormonal therapy (9%); 43% of cases were unprovoked. JAK2 V617F mutation was detected in 26% of 50 tested patients. At 3 months, 2 patients (2.1%; 95% confidence interval, 0.6-7.2) had major bleeding events (both gastrointestinal). One (1.0%) patient died due to a non-SVT-related cause, 2 had recurrent SVT (2.1%). Complete recanalization was documented in 47.3% of patients. One additional major bleeding event and 1 recurrent SVT occurred at 6 months. Rivaroxaban appears as a potential alternative to standard anticoagulation for the treatment of SVT in non-cirrhotic patients. This trial was registered at www.clinicaltrials.gov as #NCT02627053 and at eudract.ema.europa.eu as #2014-005162-29-36.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ageno W, Beyer Westendorf J, Contino L, et al. Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. Blood Adv. 2022. PMID: 35439303. doi:10.1182/bloodadvances.2022007397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。